India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India. This new route offers a faster, more convenient option for patients, with administration possible outside of hospitals.
Roche Gets Approval to Import Key Cancer Injection for Domestic Mkt New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection (Tecentriq) through subcutaneous (SC) route-under the skin injection for Indian patients.The decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs.
The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India.
"Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added.
Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight cancer.The technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme Court.In a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in India.Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic NSCLC.The committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on 12.09.2024.The committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
an hour ago
- Hans India
ORSL® Expands its Hydration Portfolio, launches ORSL® ZERO Electrolyte Drink for Calorie-Conscious Consumers
ORSL®, India's #1 Electrolyte Drink today announced the expansion of its electrolyte and hydration portfolio with the launch of ORSL® ZERO, an electrolyte drink with zero added sugar and made with real mango pulp. With this launch, Kenvue with its brand ORSL® reinforces its commitment to providing a holistic science-backed portfolio of hydration solutions that help meet the evolving and varied needs of Indian consumers. Crafted for everyday wellness, ORSL® ZERO Mango Electrolyte Drink combines three vital electrolytes with real mango pulp and zero added sugar offering hydration that is both tasty and guilt free. The new ORSL® ZERO Mango Electrolyte Drink addresses a critical gap in the hydration space offering optimal hydration with zero added sugar and great taste for diverse consumers who love nutritious indulgence. The minimal amount of calories in ORSL® Zero Electrolyte Drink are from naturally occurring sugars of mango pulp. Suitable for individuals who are calorie conscious and careful about sugar intake as part of lifestyle wellness, ORSL® ZERO Electrolyte Drink Mango eliminates the choice between guilt-free hydration and taste. It provides a delicious way to stay hydrated while helping replenish essential electrolytes for optimal wellness. ORSL® ZERO Electrolyte Drink also provides an equally viable solution to individuals' following low-carb or keto diets, practicing intermittent fasting, or engaging in regular workouts. These groups are susceptible to electrolyte loss and dehydration due to restrictive diets, intense physical activity, or reduced fluid intake. For them, this solution delivers the perfect bridge between great taste and rehydration. Commenting on the launch, Prashant Shinde, Business Head – Self-Care, Kenvue India, shared, 'In the recent years, we have seen acceleration of health and wellness with consumers increasingly seeking nutritious solutions. With ORSL® ZERO Electrolyte Drink Mango, we wanted to offer a solution to discerning consumers who are seeking rehydration solutions with indulgence of the most-loved taste of mango. The electrolyte drink promises to help deliver rehydration with the indulgence of mango, with a benefit of zero-added sugar.' Nagarajan Ramasubramaniam, Senior R&D Director, Kenvue, added, 'Non-Diarrheal Dehydration is often underestimated, especially among those with lifestyle-related or chronic health conditions. It can quietly impact energy levels, cognition and recovery. ORSL® ZERO Electrolyte Drink Mango is scientifically formulated to support rehydration with its blend of fluid and electrolytes while its zero added sugar profile makes it suitable for those conscious about calorie consumption. ORSL® Zero Electrolyte Drink Mango will be available at pharmacies, self service outlets and quick commerce platforms. This launch is a reaffirmation of Kenvue's commitment to making everyday care and wellness more inclusive for millions of consumers.
Hindustan Times
4 hours ago
- Hindustan Times
From Silent Suffering to Sleep Recovery: How Healthy Jeena Sikho is Changing the
India stands at the crossroads of a looming healthcare crisis, one that hides in bedrooms, behind closed doors, wrapped in silence and exhaustion. Every night, millions unknowingly endure the perils of sleep apnea and other chronic respiratory conditions, quietly suffering as symptoms escalate from mild fatigue to life-threatening disease. Yet, change is sweeping through Indian homes, driven not by doctors in white coats alone, but by visionary entrepreneurs who know what it means to care for a loved one. A Mission Inspired by Personal Journeys Saket Agarwal and Jatinder Verma were once united by the zeal and success typical of India's corporate elite, Agarwal as Global CEO at Spice Group, Verma steering technology for a Indian Railway BPO. Yet their defining moment came far from boardrooms, in the daunting corridors of hospitals, attending to their mothers' health struggles. This intimate encounter with India's fragmented home healthcare landscape sparked a realization: millions silently battled respiratory issues with scant awareness or access to solutions. This drove Agarwal and Verma to found Healthy Jeena Sikho (HJS), a company built not solely for commercial success but from a deep commitment to democratize respiratory and home healthcare across India. Today, HJS has evolved from a startup renting medical equipment to a comprehensive health platform that has reached over one lakh (100,000+) families, a testament to scale, impact, and trust. Unmasking India's Sleep Crisis: Facts You Can't Ignore While respiratory problems abound, obstructive sleep apnea (OSA) stands out as both widespread and underdiagnosed. Globally, about 1 billion people suffer from sleep apnea. In India, studies suggest between 10–14% of adults, often cited as 100 million+ Indians, may be affected. Yet what's truly alarming is how many cases go unnoticed: - Only 2–4% of those affected ever seek medical help - Prevalence among males can reach up to 19.7%, about double that of females Children aren't spared either—studies in Andhra Pradesh revealed 5.7% of school children aged 6–12 had OSA, underscoring a pan-India, all-age concern. Sleep apnea's effects go far beyond snoring or daytime fatigue. Left untreated, OSA raises risks of: - Hypertension: 2–3 times higher - Type 2 Diabetes: Present in 70% of moderate-to-severe cases - Stroke: 2–4 times higher likelihood - Early cognitive decline, depression, metabolic syndrome Despite these risks, Indian households often dismiss symptoms as mere tiredness, unwittingly letting a silent epidemic deepen. Sleep Apnea in India: Key Stats at a Glance - 100 million+ adults likely affected (10–14% prevalence) - 80–90% never diagnosed - Risks include heart disease, diabetes, stroke, depression - Women, children, seniors also vulnerable - Sleep study tests in hospitals often cost ₹15,000– ₹25,000, out of reach for most The Power and Value of Early Diagnosis Identifying sleep apnea early is nothing short of a lifesaver. According to both national and international research: - Early detection and CPAP therapy halt or reverse cardiovascular strain, lower blood pressure, and restore oxygen to the brain. - Quality sleep improves memory, mood, and productivity, studies show cognitive performance can improve by up to 30%. - Timely intervention cuts long-term costs of chronic disease management and avoids costly hospitalizations. - Improved well-being is visible within weeks, patients report better energy, normalized blood pressure, and renewed zest for life. Without early diagnosis, untreated sleep apnea may slowly escalate, demanding lifelong medical intervention and drastically raising healthcare costs. Breaking Barriers: Healthy Jeena Sikho's Solution Having served one lakh families, HJS saw a telling pattern, many patients needing oxygen concentrators, BiPAP, or CPAP had never been formally diagnosed. Whether due to lack of awareness, high cost, or limited sleep clinic access, the problem persisted. India's response? HJS launched the first ₹999 sleep study at home. Instead of costly, intimidating hospital stays, this at-home test offered professional-grade diagnosis, affordable, convenient, and accurate. Patients could sleep in their own bed and receive expert analysis, breaking a long-standing barrier to care. Thousands have since taken the test, many discovering their fatigue, memory issues, and blood pressure were not separate problems, but symptoms of severe sleep apnea. The Human Side: Priya's Transformation Consider Priya Sharma, 52, a homemaker in Delhi. For years, her family dismissed her headaches and irritability; snoring was the nightly background noise. When HJS launched the ₹999 sleep study, Priya's daughter insisted she try it. The verdict was clear, severe OSA. Within 48 hours, HJS provided a CPAP machine, personal mask fitting, and usage training. In just three months, Priya saw her blood pressure normalize, reported better sleep, and felt years younger. Now, her entire family is more aware and proactive about sleep health. A Business Model Built on Trust and Scale What makes HJS stand out isn't just its innovative diagnosis; it's the company's one-stop healthcare platform: - Comprehensive Rentals: Hospital beds, BiPAP/CPAP devices, oxygen concentrators, wheelchairs—all delivered quickly and maintained professionally - Rapid Response: Same-day delivery in key cities, thanks to regional warehouses and ready stock - Expert Support: Trained respiratory technicians, not generic delivery staff; live 24x7 helpline support - Doctor Partnerships: Growing network of referring GPs and pulmonologists, ensuring continuity of care - Quality Assurance: Partnerships with leading global brands are ResMed, Philips, Oxymed, BMC, promise safe and effective solutions Presence and Impact: - Serving 15+ cities with pan-India delivery - Over 100,000 families cared for - Consistent 5-star Google ratings and a 35% customer referral rate, clear markers of trust and loyalty Data-Driven Approach and Societal Impact HJS's commitment to data goes beyond numbers. When founders found that 20% of senior business leaders in their network needed urgent respiratory support, it signalled a deeper crisis affecting even the most health-aware groups. Moreover, a striking 35% recurrence rate among respiratory device users pointed to chronic, under-managed conditions and highlighted the need for ongoing care and health literacy. HJS responded with digital outreach—blogs, videos, and campaigns that have reached 1.5 million+ viewers, raising public awareness while empowering families to seek answers. Redefining Healthcare for India's Future India is forecasted to double its senior citizen population by 2050, with non-communicable diseases on the rise. Hospitals alone cannot absorb this strain. Companies like HJS are building parallel, scalable healthcare infrastructure, empowering homes to become frontline care centers, not just end-points. From affordable sleep studies to empathetic post-diagnosis service, HJS sets a benchmark—proving that prevention, convenience, and compassion can drive better health outcomes for everyone. 'We started with rentals,' Agarwal reflects. 'But now we're driving a movement for accessible, preventive healthcare—one home, one family at a time.' The Sound of Renewal The soft hum of a CPAP machine in households across India is not just a sign of illness, it is the melody of renewed health, dignity, and hope. Each restful night achieved marks a quiet victory against an epidemic hidden in plain sight. Healthy Jeena Sikho, by blending technological innovation, empathetic service, and community education, isn't just supporting recovery—it's restoring lives. For more information, media inquiries, or to book a home sleep study: 📩 info@ 🌐 Disclaimer: This article is sponsored content curated by HT Syndication. The inputs and details accounted for in the article do not necessarily reflect those of HT, and HT does not endorse or assume any responsibility for the information provided. Want to get your story featured as above? click here!
Business Standard
5 hours ago
- Business Standard
Mari State University and Max Healthcare Sign Strategic MoU to Enhance Medical Education and India-Russia Collaboration
SMPL Yoshkar-Ola [Russia], August 12: In a significant step toward strengthening Indo-Russian ties in medical education, Mari State University, a leading destination for students pursuing MBBS in Russia, has signed a Memorandum of Understanding (MoU) with Max Healthcare, one of India's most respected and internationally acclaimed medical organizations. The signing took place during the official visit of Mr. Venkateswara Vinay Kumar, Minister of Education and Social Welfare at the Embassy of India in Moscow, to Yoshkar-Ola, Republic of Mari El. This landmark agreement lays the foundation for a long-term strategic partnership aimed at introducing global best practices in medical training, fostering academic mobility, and facilitating the transfer of medical knowledge between India and Russia. The collaboration was facilitated with the support of Rus Education, a trusted partner for Indian students seeking MBBS in Russia, and a key player in strengthening educational ties between the two nations. Rus Education has been instrumental in guiding thousands of Indian students to pursue medical education at reputed Russian universities like Mari State University. The MoU marks a collaborative effort to launch joint educational and skill enhancement programs starting this year. These programs will benefit both the medical students of Mari State University and practicing healthcare professionals in the Republic of Mari El. With the active involvement of Max Healthcare's experienced medical faculty, the curriculum will incorporate modern Indian medical techniques, hands-on clinical training, and medical English language instruction. A key focus of the partnership is the enhancement of English language proficiency, enabling students and professionals to engage effectively in international medical settings and collaborative clinical research. As part of the program, participants will also have the opportunity to visit Max Healthcare's clinical facilities in India and learn directly from some of the country's top medical practitioners. The MoU signing ceremony was attended by high-ranking officials from the Republic of Mari El, including Deputy Chairman of the Government, Minister of Culture, Press, and National Affairs Mr. Konstantin Ivanov, and Minister of Health Mr. Vladimir Gladnev. They expressed strong confidence in the initiative, emphasizing that this partnership represents not only a new chapter in the region's healthcare development but also a deepening of trust and cooperation between India and Russia. For over a decade, Mari State University has been at the forefront of international medical education in Russia, especially for students from India. With the support of Rus Education, the university continues to rank among the top Russian institutions in terms of Indian student enrollment. This collaboration with Max Healthcare reaffirms Mari State University's commitment to integrating world-class medical education into its MBBS programs and preparing globally competent medical professionals. Rus Education, in its ongoing mission to offer ethical, transparent, and student-centric guidance, views this partnership as another opportunity to enrich the academic and clinical exposure of Indian students choosing to study MBBS in Russia.
